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We show that a common polymorphic variant in the
ERCC5 5′ untranslated region (UTR) generates an up-
stream ORF (uORF) that affects both the background ex-
pression of this protein and its ability to be synthesized
following exposure to agents that cause bulky adduct
DNA damage. Individuals that harbor uORF1 have a
marked resistance to platinum-based agents, illustrated
by the significantly reduced progression-free survival of
pediatric ependymoma patients treated with such com-
pounds. Importantly, inhibition of DNA-PKcs restores
sensitivity to platinum-based compounds by prevent-
ing uORF1-dependent ERCC5 expression. Our data sup-
port a model in which a heritable 5′ noncoding mRNA
element influences individuals’ responses to platinum-
based chemotherapy.
Supplemental material is available for this article.
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Many commonly used chemotherapeutic drugs, such as
cisplatin, exert their cytotoxic affects by causing DNA
damage in the form of intrastrand and interstrand cross-
links (Koberle et al. 2010; Galluzzi et al. 2011). In response
to these lesions, cells initiate a complex series of signaling
cascades that coordinate cell cycle arrest and DNA repair
(collectively referred to as the DNA damage response
[DDR]) (Bartek and Lukas 2007; Jackson and Bartek 2009).
Importantly, the expression levels and activities of com-
ponents of the DDR play a pivotal role in the response
of tumors to therapy (Jackson and Bartek 2009; Helleday
2011).
Activation of the DDR by agents that cause bulky ad-
duct damage, such asUV irradiation or cisplatin, increases
the transcription of hundreds of genes, including genes
directly involved in nucleotide excision repair (NER), the
DNA repair pathway that removes these lesions (Rieger
andChu2004; Boermaet al. 2005; daCosta et al. 2005).Ad-
ditionally, in response to UV irradiation, many critical
components of the NER pathway are also controlled at
the level of translation (Deng et al. 2002; Powley et al.
2009). For translation initiation, the eukaryotic initiation
factor 4F (eIF4F) complex binds to the mRNA and recruits
the ribosome and the ternary complex (comprised of
eIF2, GTP, and tRNAimet), which delivers the initiator
tRNAimet to the start codon (Sonenberg and Hinnebusch
2009). Formation of the ternary complex can by controlled
by four upstream kinases (PERK, PKR, HRI, and GCN2)
that phosphorylate eIF2 on the α subunit, causing seques-
tration of this protein in an inactive complex with its GEF
eIF2B (Sonenberg and Hinnebusch 2009).
We showed previously that, in response to a nonlethal
dose of UVB, signaling via DNA-PKcs to GCN2 results
in a reduction in the global rate of protein synthesis medi-
ated by an increase in the phosphorylation of eIF2α (Fig.
1A;Deng et al. 2002; Powley et al. 2009). However, despite
the general repression of translation that occurs following
UVB exposure, ∼8% of transcripts, including mRNAs
encodingNERproteins, are recruited to translationally ac-
tive polysomes concurrent with an increase in the transla-
tional efficiency of these mRNAs (Powley et al. 2009).
The translation of proteins required for the DDR is de-
pendent on sequence elements within the 5′ untranslated
regions (UTRs) of their mRNAs that are referred to as up-
streamORFs (uORFs) (Le Quesne et al. 2010; Somers et al.
2013). Under stress conditions, when increased eIF2α
phosphorylation lowers the availability of the eIF2 ternary
complex, translation of some mRNAs containing uORFs
are up-regulated, although the mechanisms by which
uORFs function are not yet fully understood (for review,
see Somers et al. 2013).
Given the role of uORFs in the DDR, one testable hypo-
thesiswould be that polymorphisms that create or remove
upstreamAUGcodons (Deng et al. 2002; Calvo et al. 2009;
Powley et al. 2009) in NER genes could contribute to the
differential responses of patients to chemotherapeutic
agents. Interestingly, ERCC5 (a structure-specific en-
donuclease that cleaves 3′ of the DNA adduct and is an in-
dispensable core protein of the NER machinery) contains
uORFs, one of which is generated by the polymorphic var-
iant rs751402 that is present in 35% of the white Cauca-
sian population. Here we show that this uORF regulates
the synthesis of ERCC5 following exposure to agents
that cause bulky adduct DNA damage, that signaling
through DNA-PKcs is required for the increased uORF-
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regulated translation of ERCC5 following cisplatin expo-
sure, and, importantly, that rs751402 is a prognostic indi-
cator for poor progression-free survival of patients with
childhood ependymoma treated with
platinum-containing compounds.
Results and Discussion
The 5′ UTR of ERCC5 contains a
functional uORF that is required for
expression of the downstream cistron
following bulky adduct DNA damage
The polymorphism rs751402, which is
located in the 5′ UTR of ERCC5, is
present in 35% of thewhite Caucasian
population (Fig. 1Bi). This polymor-
phism generates a uORF (termed
uORF1) (Fig.1Bii). The two variants
are referred to as the “G” allele (no
uORF1) or the “A” allele (uORF1).
uORF1 lies243basesupstreamof a sec-
onduORF(termeduORF2)and420bas-
es upstream of the physiological AUG
start codon (Supplemental Fig. 1A).
To test the hypothesis that the
polymorphism could be associated
with altered expression of endogenous
ERCC5,Western blot analysis was car-
ried out on either A/A orG/G cell lines
derived from patients with neuroblas-
toma or B cells derived from healthy
individuals. The data show that cell
lines homozygous for the ERCC5
“A” allele expressed a significantly
lower level of ERCC5 protein with no
such difference detectable in the levels
of RNA expression (Fig. 1Ci,Cii). We
reasoned that the difference in expres-
sion of ERCC5 from these transcripts
could be due to the presence of the ad-
ditional uORF1, and, in support of
this, sequencing of the entire 5′ UTR
of the G/G or A/A cell lines revealed
no other sequence differences (Supple-
mental Fig. 1B). To investigate
the impact of the rs751402 polymor-
phism upon translation of the down-
stream cistron in a cell culture-based
system, the 5′ UTR of ERCC5 was
subcloned upstream of the luciferase
coding sequence to generate three con-
structs: pUTR-A (containing both
uORF1 and uORF2), pUTR-G (con-
taining uORF2), and a control con-
struct, pUTR-MUT, in which the 5′
UTR of ERCC5 contained no uORFs
(both AUGs were mutated to AUA)
(Fig. 1Di). The plasmids were trans-
fected into HeLa cells, and the lucifer-
ase activity was determined. These
data show that uORF2-containing
transcripts showed repressed transla-
tion relative to pUTR-MUT; however,
uORF1 (rs751402 SNP pUTR-A) led
to further inhibition (Fig. 1Dii). To ensure that transla-
tion was initiated at the AUG codons found at the start
of uORF1 anduORF2, the luciferase constructs containing
Figure 1. A polymorphism in a uORF controls ERCC5 translation. (A) Schematic diagram of
signaling from bulky adduct damage to the inhibition of translation: When cells are exposed
to bulky adduct damage (e.g., UVB light), there is a shutdown of translation and reprogramming
of the translational machinery that permit the selective up-regulation of DNA repair enzymes at
the level of translation. We showed previously that signaling from DNA-PKcs to phosphoryla-
tion of eIF2α is essential for this response, since, in the presence of a DNA-PKcs inhibitor, in
DNA-PKcs deficient cell lines, and following depletion of DNA-PKcs levels by siRNA, the trans-
lational shutdown and selective translational reprogramming that are part of the normal re-
sponse are inhibited (Powley et al. 2009). (Bi) Global distribution of the polymorphism
rs751402. The derived “A” allele is present in ∼35% of white Caucasians. (Bii) Schematic repre-
sentation of the uORFs present in ERCC5. (Ci,Cii) The levels of ERCC5 protein expression differ
with genotype, with no corresponding changes in the levels of the mRNA. Levels of ERCC5 in
neuroblastoma cell lines (derived from individual patients) or B-cell lines (derived from healthy
individuals), each representing A/A or G/G genotypes, were determined by Western analysis.
Parallel samples were taken, and the level of mRNA was assessed by quantitative PCR
(qPCR). (∗) P < 0.05; (∗∗) P < 0.01. (Di) Schematic diagram of the plasmids containing the alterna-
tive 5′ UTRs of ERCC5. pUTR-A contains both uORF1 and uORF2, and pUTR-G contains
uORF2. pUTR-MUT contains no uORFs (both uORF AUGs mutated to AUA). (Dii) HeLa cells
were transfected with the plasmids indicated and a β-galactosidase transfection control. After
48 h, cells were harvested and assayed for luciferase activity. pUTR-A caused the strongest inhi-
bition of luciferase activity. (Black bars) pUTR-MUT; (red bars) pUTR-A; (white bars) pUTR-G.
(∗) P < 0.05.
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the 5′ UTRs of the two variants of the ERCC5 sequence
were modified such that the AUGs of the uORFs were
in-frame with the luciferase start codon (Supplemental
Fig. 1Ci). RNAs generated from these vectors were used
to prime rabbit reticulocyte lysates, and the data show
that ribosomes can recognize and initiate from the AUG
codons in both uORFs (Supplemental Fig. 1Cii).
To confirm whether the ERCC5 uORF1 translationally
regulates the expression of a reporter protein in response
to bulky adduct DNA damage, cells were transfected
with the reporter constructs and then treatedwith cisplat-
in (Fig. 2Ai) orUVB (Fig. 2Aii). In each case, the translation
from the construct with no uORFs (pUTR-MUT) or only
uORF2 (pUTR-G) was repressed by the treatments (con-
sistent with a global decrease in translation rates due to
phosphorylation of eIF2α). However, synthesis from the
rs751402 SNP pUTR-A construct remained significantly
higher, demonstrating that uORF1 augments translation
following DNA damage (Fig. 2A).
These data strongly suggest that uORF1 is required for
expression of the downstream cistron following exposure
to compounds that elicit bulky adduct DNA damage.
ERCC5 transcripts that harbor uORF1 confer
resistance to cisplatin exposure
Since platinum-based chemotherapy is used as a frontline
treatment for a range of tumors (Galluzzi et al. 2011), we
hypothesized that the polymorphism, by facilitating
ERCC5 protein expression, could affect the sensitivity of
cells to these compounds. Thirteen cell lines representa-
tive of the three different genotypes, including cell lines
derived from patients with neuroblastoma and diffuse
large B-cell lymphoma (DLBCL) and from healthy individ-
uals of fibroblast and B-cell origin, were incubatedwith in-
creasing doses of cisplatin. The percentage of cell survival
was determined in each case by using WST1 assays (Sup-
plemental Fig. 2A–E), and, using these data, SF50s (the cis-
platin concentrations required to reduce 50% of the cell
population) were calculated by a logarithmic regression.
In each group of cell types, there was relatively higher sur-
vival of those that contained the “A” allele (A/A or A/G)
when compared with cells that are homozygous for the
“G” allele (Fig. 2B).
To assess the effects that uORF1 had on endogenous
ERCC5expression in response to cisplatin exposure, neuro-
blastoma and B-cell lines representative of all three
genotypes were used. All genotypes showed substantial re-
ductioninglobalproteinsynthesis rateswithcisplatintreat-
ment, as assessed by methionine incorporation (Fig. 3Ai,
Aii). To determine how cisplatin exposure affected ERCC5
expression among the different genotypes, Western blot
analysis and quantitative PCR (qPCR) were performed in
parallel (Fig. 3Bi,Bii,Ci,Cii). In all cell lines, therewas an in-
crease in eIF2α phosphorylation following exposure to cis-
platin (Fig. 3Bi,Ci), consistent with the reduction in global
protein synthesis rates. However, in cell lines that contain
the ERCC5 transcripts with uORF1 (both A/A and A/G),
there was maintenance of ERCC5 protein expression after
exposure to cisplatin. In contrast, cells homozygous for
the “G” allele showed a decrease in expression of this pro-
tein with an increasing dose of cisplatin (Fig. 3Bi,Ci). There
was no significant increase in the levels of ERCC5mRNA
(Fig. 3Bii,Cii). Consistent with an enhanced translation
rate, we show that the “A” allele ERCC5 transcripts were
specifically maintained on polysomes (actively translating
ribosomes) in response to cisplatin, while “G” allele tran-
scripts shifted toward lighter polysomes (less actively trans-
lating ribosomes) in heterozygote cell lines (Supplemental
Fig. 3). Pulse-labelled immunoprecipitations to examine
ERCC5’s half-life confirmed that the loss of ERCC5protein
expression after cisplatin treatment is solely due to transla-
tional inhibition (Supplemental Fig. 4).
To confirm the link between induction of ERCC5 and
repair of cisplatin-induced DNA damage, competitive
ELISAs were carried out to assess the degree of cisplatin
adducts that remained in cells derived from neuroblasto-
mas (Fig. 3Biii) or B cells (Fig. 3Ciii) at 24 or 16 h of ex-
posure to this compound, respectively. The data show
that significantly more competition (indicating higher
Figure 2. The 5′ UTR of ERCC5 contains a uORF that promotes
translation in response to bulky adduct DNA damage. (Ai,Aii) HeLa
cells were transfected with the plasmids indicated and then exposed
to cisplatin (Ai) or UVB (Aii) and harvested at the times indicated.
Cells were then lysed, and the luciferase activity was determined.
When exposed to DNA damage, cells containing the pUTR-A plas-
mid show significantly higher luciferase activity. (Black bars)
pUTR-MUT; (red bars) pUTR-A; (white bars) pUTR-G. (∗) P < 0.05;
(∗∗) P < 0.01; (∗∗∗) P < 0.001. (B) Cisplatin SF50 values. WST1 assays
were performed on a panel of cell lines. Cell lines derived from pa-
tients with neuroblastoma were either LAN5 (G/G), CHP-212
(A/A), or SH-SY5Y (A/G). Cell lines derived frompatients with diffuse
large B-cell lymphoma (DLBCL) were either DOHH-2 (G/G) or DB
(A/G). Fibroblasts derived from healthy individuals were either
AG06558 (G/G), TIG120 (G/G), GM17082 (A/A), GM17301 (A/G),
or TIG114 (A/G). B cells derived from healthy individuals were
GM07019 (G/G),GM07029 (A/A), orGM07348 (A/G). These cell lines
were treated with a range of cisplatin concentrations (see Supplemen-
tal Fig. 2) for 24 h (except B cells that were treated for 16 h), and SF50s
(the cisplatin concentrations required to kill 50% of a cell population)
were calculated bya logarithmic regression.The graph showsthe SF50
mean values and standard error of the mean from three independent
experiments. For the 13 cell lines used, therewas a significantly lower
survival of cells that were homozygous for the “G” allele.
Translation regulation of ERCC5 via a uORF
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cisplatin adduct levels) was provided from the cell lines
whose ERCC5 transcripts lack the uORF1 (G/G), imply-
ing that these cells have slower repair rates (Fig. 3Biii,Ciii).
Collectively, these data suggest that tumors that arise
in individuals that harbor at least one ERCC5 “A” allele
(rs751402 uORF1) are likely to be refractory to plati-
num-based chemotherapy as a result
of the translational up-regulation of
this protein.
Translational control of ERCC5
is downstream from DNA-PKcs
Following bulky adduct DNA damage,
signaling throughDNA-PKcs (acritical
DNAdamagekinase) is required for the
selective translational activation of
NER enzymes in response to UVB irra-
diation, and phosphorylation of eIF2α
links DNA damage sensing to protein
synthesis regulation (Powley et al.
2009). Therefore, we hypothesized
that resistant “A” allele-expressing
cells could be sensitized to cisplatin
by DNA-PKcs inhibition (Supplemen-
tal Fig. 5A). B cells were pretreated
with the DNA-PKcs inhibitor Nu7441
(Supplemental Fig. 5B; Hardcastle
et al. 2005) and exposed to 50 µM cis-
platin, and survival assays were per-
formed. The data show that, in the
presence of the DNA-PKcs inhibitor,
the differential response to cisplatin
was ablated and became independent
of the genotype (Fig. 4A). Western blot
analysis confirmed inhibition of eIF2α
phosphorylation byNu7441 and atten-
uation of the induction of ERCC5 in
rs751402 “A” allele-expressing cells
(Fig. 4B; Supplemental Fig. 5Ci,Cii,
Ciii), with no such change in the
ERCC5 RNA levels (Fig. 4C). To con-
firm a role for eIF2α phosphorylation
in this process, cells that contained
the “A” allele of ERCC5 were trans-
fected with plasmids encoding the
eIF2α phosphatase GADD34 (Supple-
mental Fig. 5A). The data show that
direct inhibition of eIF2α phosphoryla-
tion was sufficient to inhibit the
increase inERCC5expression after cis-
platin exposure, strongly supporting a
role for eIF2α in this process (Supple-
mental Fig. 5D).
The polymorphism is prognostic




The in vitro cisplatin resistance of the
“A” allele variant of ERCC5 led us to
hypothesize that cancer patients who
carried the “A” allele would be more
refractory to platinum chemotherapy due to relatively
high rates of repair of platinum–DNA adducts within tu-
mors. Testing this hypothesis at the clinical level required
a tumor type that fulfilled the following importantcriteria:
The primary adjuvant therapy was platinum-based and
was not confounded by the addition of other adjuvant
Figure 3. A uORF in the 5′ UTR of ERCC5 promotes resistance to cisplatin in vitro. (Ai,Aii)
Neuroblastoma cell lines (Ai) or B-cell lines (Aii) derived from healthy individuals for all three
rs751402 genotypes were treated with cisplatin at the doses shown, and methionine incorpora-
tion was measured to assess the degree of inhibition of global protein synthesis rates. There
were no significant differences in the degrees of inhibition of protein synthesis between the three
B-cell lines or the three neuroblastoma-derived cell lines. (Solid bars) Control conditions; (hatched
bars) cells treated with cisplatin. (Bi–Biii,Ci–Ciii) The three neuroblastoma cell lines (Bi–Biii) or
the three B-cell lines (Ci–Ciii) of each ERCC5 5′ UTR rs751402 genotype were treated with the
doses of cisplatin shown, and protein and RNA samples were obtained. (Bi,Ci) Protein samples
were separated by SDS-PAGE and immunoblotted. The data show that, in all cases, eIF2α is phos-
phorylated by treatment of cells with cisplatin with no change in the total levels of eIF2α. In each
case, with increasing doses of cisplatin in the cell lines that were homozygous for the “G” allele,
there was a marked decrease in ERCC5. In contrast, when the cells lines that contain the ERCC5
5′ UTR “A” allele (either the homozygous or heterozygous cell lines) were treated with cisplatin,
the expression of ERCC5 protein was maintained. (Bii,Cii) The level of ERCC5 mRNA was as-
sessed by qPCR, and no significant increases were detected. (Biii,Ciii) A competitive ELISA
was used tomeasure platinum adduct levels in cisplatin-treated neuroblastoma and B cells. Cells
were treated with cisplatin at the doses shown. DNA was then extracted, and equal concentra-
tions were used to perform a competitive ELISA against a standard of platinated DNA with the
monoclonal antibody (CP9/19) that recognizes guanine intrastrand cross-links formed by cisplat-
in. Plotted is the mean absorbance normalized to competition with DMF DNA (100%) for the
neuroblastoma cells (Biii) or B cells (Ciii). In both cell lines, the G/G genotype provided signifi-
cantly more competition, demonstrating a higher adduct level. (∗) P < 0.05; (∗∗) P < 0.01.
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treatment. For these salient reasons, we chose to study the
outcomes in ependymoma in very young children treated
in two clinical trials (Grill et al. 2001; Grundy et al.
2007). Ependymoma is the thirdmost commonmalignant
brain tumor in children, accounting for 12%of all brain tu-
mors, and the 5-year survival rates range from39% to 64%
(Kilday et al. 2009). Early childhood ependymoma also ex-
hibits low genetic heterogeneity (SupplementalMaterial).
The current frontline therapy for ependymoma is surgical
resection followed by radiotherapy, which has reasonable
response rates.However, this can lead to significant seque-
lae for the developing CNS, such as neuropsychological
and cognitive defects later in life. Therefore, efforts have
been made to use adjuvant chemotherapy based on plati-
numagents (cisplatin and carboplatin) in place of radiation
inveryyoungpatients (Grill et al. 2001;Grundyetal. 2007).
The distribution of theERCC5 rs751402 polymorphism in
ependymoma patients was examined using allele-specific
PCR on genomic DNA extracted from 55 post-operative
frozen tumor tissue samples, and progression-free survival
rates were analyzed (Fig. 5; Supplemental Tables 1,2).
These data show that patients that express an “A” allele
(uORF1) ERCC5 transcript have significantly reduced pro-
gression-free survival (P = 0.016) and multivariate hazard
ratio of 3.63 (95% CI [confidence interval]; 1.69 and 7.76)
(Fig. 5; Supplemental Table 1). The rs751402 genotype
did not affect the overall survival of ependymoma patients
(P = 0.108), most likely because patients who failed to re-
spond to primary chemotherapy subsequently received ra-
diotherapy,which creates double-strandbreaks—a formof
DNA damage not repaired by the NER pathway.
Overall, these data would strongly suggest that the
rs751402 polymorphism is an independent prognostic fac-
tor for progression-free survival of platinum-treated epen-
dymoma in early childhood patients.
In our study, we provided mechanistic data to show for
the first time how a polymorphism in a 5′ UTR can create
an RNA regulatory element that influences cell fate. The
data presented here have very important implications
for the treatment of ependymoma with platinum-based
compounds. Given the prevalence of polymorphic vari-
ants that create or remove uORFs in humans (Calvo
Figure 4. Otherwise resistant cells are sensitized to cisplatin treat-
ment by inhibiting DNA-PKcs activity. (A) The three B-cell lines
were incubated with either DMSO/DMF (solvent control; black
bars), 1 µM DNA-PKcs inhibitor Nu7441 (black hatched bars),
50 µM cisplatin (green bars), or a combination of Nu7441 and cisplat-
in (green hatched bars), and the survival rates were determined. The
data show that cells that contained the “A” allele had a statistically
significant higher survival rate after cisplatin treatment. However,
pretreatment with Nu7441 rendered all cell genotypes equally sensi-
tive to cisplatin. (∗) P < 0.05. (B) Extracts were generated from cells
treated as above and were separated by SDS-PAGE and immunoblot-
ted with the antibodies shown. The data show that, in the presence of
the DNA-PKcs inhibitor and cisplatin, there is a decrease in the phos-
phorylation of eIF2α and a corresponding decrease in the level of
ERCC5 in the cell lines that contain the “A” allele (see Supplemental
Fig. 5 for quantification). (C ) The level of ERCC5mRNAwas assessed
from parallel samples by qPCR, and no changes corresponding to dif-
ferential protein expression were detected.
Factor Univariate Multivariate 
HR 95 % CI P HR 95 % CI P
Location
ST (n = 10)
PF (n = 45)
1
0.75 0.33 1.71 0.492 - - -
WHO grade (1 MD)
II (n = 15)
III (n = 39)
1
2.25 1.03 4.94 0.042
1
3.31 1.43 7.65 0.005
Sex
Female (n = 17)
Male  (n = 38)
1
0.67 0.34 1.32 0.252 - - -
Surgery
CR (n = 38)
IR (n = 17)
1
1.08 0.55 2.11 0.831 - - -
Genotype
G/G (n = 40)
A/A  or A/G (n = 15)
1
2.28 1.13 4.58 0.021
1
3.63 1.69 7.76 0.001
A






















Progression-free survival (years) 
Figure 5. The polymorphism in ERCC5 is prognostic for sensitivity
to platinum-based chemotherapy in early childhood ependymoma.
(A) Clinicopathological data from primary ependymoma patients ob-
tained from Children’s Cancer and Leukaemia Group (CCLG) or So-
ciété Française d’Odontologie Pédiatrique (SFOP). All 55 children
were below 5 years of age at diagnosis and had been treated only
with primary post-operative platinum chemotherapy (cisplatin/car-
boplatin) (Grill et al. 2001; Grundy et al. 2007). This was in adherence
to two concordant European pediatric clinical trials: CCLGCNS9204
(Grundy et al. 2007) (n = 41) and Baby Brain SFOP (BBSFOP) (Grill et al.
2001) (n = 14). Probability (P) values for univariate and multivariate
survival analysis were obtained by the Cox proportional hazard mod-
el. (PF) Posterior fossa; (ST) supratentorial; (IR) incomplete resection;
(CR) complete resection; (HR) hazards ratio; (95%CI) 95%confidence
interval; (MD) missing data. (B) Kaplan-Meier plot of progression-free
survival of ependymoma patients treated with platinum chemother-
apy that were homozygous for the “G” allele (blue line) or contained
the “A” allele (A/G or A/A; red line).
Translation regulation of ERCC5 via a uORF
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et al. 2009), there may well be other such elements that
have the potential to modify an individual’s sensitivity
to a range of agents. These warrant further investigation.
Materials and methods
Cell culture
HeLa cells were cultured as described (Powley et al. 2009). TIG fibroblasts
were from the Japanese Collection of Research Bioresources (JCRB) and
were cultured according to the JCRB Cell Bank (http://cellbank.nibio.go.
jp). B cells and fibroblastswere fromCoriell Cell Repositories andwere cul-
tured according to the Coriell Cell Repositories site (http://ccr.coriell.org).
Neuroblastoma cells were from American Type Culture Collection (ex-
cept for the LAN5 cell line, which was obtained from Charles-Henry Gat-
tolliat, InstituteGustaveRoussy, Villejuif, France). DLBCL cells were a gift
from Professor M. Dyer, University of Leicester. B cells naturally form
clumps in culture that can induce cellular stress signaling pathways.
To minimize these effects, clumps were dispersed during treatments and
1 h prior to harvest.
Cells treatments
Cells were exposed to UVB as described (Powley et al. 2009). Cisplatin was
dissolved in DMF and added to B cells or HeLa for 16 h or to neuroblasto-
ma, DLBCL, and fibroblasts for 24 h. Nu7441 (1 µM) was added 30min pri-
or to cisplatin. All experiments were performed on at least three separate
occasions.
Transient transfections and reporter gene assays
Transient transfections and measurements of luciferase activity were as
described (Kong et al. 2008; Powley et al. 2009). Luciferase values were ex-
pressed relative to the transfection control β-galactosidase, or, for cisplatin
and UVB DNA damage treatments, the values were expressed relative to
luciferase RNA levels determined by qPCR. All values were normalized
to the level of the “no uORFs”mutant pUTR-MUT,whichwas set to a val-
ue of 1.0. All experiments were performed on at least three independent
occasions.
Additional details about the Materials and Methods are provided in the
Supplemental Material.
Acknowledgments
We acknowledge the help of Nicole Brousse from the Tumor Bank from
Necker Sick Children Hospital. This work was supported by funding from
Cancer Research UK (to A.K., J.S., and L.A.W.); the Biotechnology and Bio-
logical Sciences Research Council (professorial fellowship to A.E.W.); the
Medical Research Council (Senior Fellowship to M.B., and Medical Re-
search Council program funding to A.E.W.); and the Societe Francaise des
Cancers de l’Enfant/Enfants et Sante, Etoile deMartin, and FondationCar-
refour (to J.G. and S.P.). Ependymoma research within the Children’s Brain
Tumour Research Centre is funded by the Joe Foote Foundation. J.-P.K. is a
JamesTudorClinical Research Fellow in PaediatricNeuro-Oncology at the
Children’s Brain Tumour Research Centre, United Kingdom.
References
Bartek J, Lukas J. 2007. DNA damage checkpoints: from initiation to re-
covery or adaptation. Curr Opin Cell Biol 19: 238–245.
BoermaM, van derWees CGC, Vrieling H, Svensson JP,Wondergem J, van
der Laarse A,Mullenders LHF, vanZeelandAA. 2005.Microarray anal-
ysis of gene expression profiles of cardiac myocytes and fibroblasts af-
ter mechanical stress, ionising or ultraviolet radiation. BMC
Genomics 6: 6.
Calvo SE, Pagliarini DJ, Mootha VK. 2009. Upstream open reading frames
cause widespread reduction of protein expression and are polymorphic
among humans. Proc Natl Acad Sci 106: 7507–7512.
da Costa RMA, Riou L, Paquola A, Menck CFM, Sarasin A. 2005. Tran-
scriptional profiles of unirradiated or UV-irradiated human cells ex-
pressing either the cancer-prone XPB/CS allele or the noncancer-
prone XPB/TTD allele. Oncogene 24: 1359–1374.
Deng J, Harding HP, Raught B, Gingras AC, Berlanga JJ, Scheuner D, Kauf-
man RJ, Ron D, Sonenberg N. 2002. Activation of GCN2 in UV-irradi-
ated cells inhibits translation. Current Biol 12: 1279–1286.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M,
Kroemer G. 2011. Molecular mechanisms of cisplatin resistance. On-
cogene 31: 1869–1883.
Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn
A, Habrand JL, Doz F, Frappaz D, Gentet JC, et al. 2001. Postoperative
chemotherapy without irradiation for ependymoma in children under
5 years of age: a multicenter trial of the French Society of Pediatric On-
cology. J Clin Oncol 19: 1288–1296.
Grundy RG, Wilne SA, Weston CL. 2007. Primary postoperative che-
motherapy without radiotherapy for intracranial ependymoma in
children: the UKCCSG/SIOP prospective study. Lancet Oncol 8:
761–761.
Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, StockleyM,
Golding BT, Rigoreau L, Richardson C, Smith GC, et al. 2005. Discov-
ery of potent chromen-4-one inhibitors of the DNA-dependent protein
kinase (DNA-PK) using a small-molecule library approach. J Med
Chem 48: 7829–7846.
Helleday T. 2011. The underlying mechanism for the PARP and BRCA
synthetic lethality: clearing up the misunderstandings. Mol Oncol 5:
387–393.
Jackson SP, Bartek J. 2009. The DNA-damage response in human biology
and disease. Nature 461: 1071–1078.
Kilday J-P, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B, Grundy R. 2009.
Pediatric ependymoma: biological perspectives. Mol Cancer Res 7:
765–786.
Koberle B, Tomicic MT, Usanova S, Kaina B. 2010. Cisplatin resistance:
preclinical findings and clinical implications. Biochim Biophys Acta
1806: 172–182.
Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL,
Meijer HA, Dobbyn HC, Stoneley M, Spriggs KA, et al. 2008. The
mechanism of micro-RNA-mediated translation repression is deter-
mined by the promoter of the target gene. Proc Natal Acad Sci 105:
8866–8871.
Le Quesne J, Spriggs K, Bushell M,Willis A. 2010. Dysregulation of protein
synthesis and disease. J Pathol 220: 140–151.
Powley I, Kondrashov A, Young LA, Dobbyn HC, Hill K, Cannell IG,
StoneleyM. 2009. Translational reprogramming following UVB irradi-
ation is mediated by DNA-PKcs and allows selective recruitment to
the polysomes of mRNAs encoding DNA repair enzymes. Genes
Dev 23: 1207–1220.
Rieger KE, ChuG. 2004. Portrait of transcriptional responses to ultraviolet
and ionizing radiation in human cells. Nucleic Acids Res 32:
4786–4803.
Somers J, PöyryT,Willis AE. 2013. A perspective onmammalian upstream
open reading frame function. Int J Biochem Cell Biol 45: 1690–1700.
Sonenberg N, Hinnebusch AG. 2009. Regulation of translation initiation
in eukaryotes: mechanisms and biological targets. Cell 136: 731–
745.
Somers et al.
1896 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on January 22, 2019 - Published by genesdev.cshlp.orgDownloaded from 
 10.1101/gad.261867.115Access the most recent version at doi:
 originally published online September 3, 201529:2015, Genes Dev. 
  
Joanna Somers, Lindsay A. Wilson, John-Paul Kilday, et al. 
  
ORF that confers resistance to platinum-based chemotherapy
















License (Attribution-NonCommercial 4.0 International), as described at 




 click here.right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the top
© 2015 Somers et al.; Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on January 22, 2019 - Published by genesdev.cshlp.orgDownloaded from 
